Skopos Labs, Inc. Neurocrine Biosciences Inc Transaction History
Skopos Labs, Inc.
- $330 Million
- Q4 2024
A detailed history of Skopos Labs, Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Skopos Labs, Inc. holds 231 shares of NBIX stock, worth $33,093. This represents 0.01% of its overall portfolio holdings.
Number of Shares
231
Previous 116
99.14%
Holding current value
$33,093
Previous $13,000
138.46%
% of portfolio
0.01%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding NBIX
# of Institutions
632Shares Held
93.9MCall Options Held
632KPut Options Held
621K-
Black Rock Inc. New York, NY14.2MShares$2.03 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$1.43 Billion0.02% of portfolio
-
State Street Corp Boston, MA5.15MShares$738 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$369 Million0.47% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.86MShares$267 Million3.62% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.7B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...